CN104758294A - Inhalation pharmaceutical composition used for treatment of chronic obstructive pulmonary disease (COPD) and asthma and preparation method thereof - Google Patents
Inhalation pharmaceutical composition used for treatment of chronic obstructive pulmonary disease (COPD) and asthma and preparation method thereof Download PDFInfo
- Publication number
- CN104758294A CN104758294A CN201410790703.9A CN201410790703A CN104758294A CN 104758294 A CN104758294 A CN 104758294A CN 201410790703 A CN201410790703 A CN 201410790703A CN 104758294 A CN104758294 A CN 104758294A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- budesonide
- tiotropium bromide
- carrier
- asthma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides a pharmaceutical composition used for treating COPD and bronchial asthma, and a preparation method thereof. The pharmaceutical composition comprises active ingredients and a pharmaceutically-acceptable carrier, wherein the active ingredients comprise formoterol fumarate dihydrate, budesonide and tiotropium bromide hydrate, the weight percentages of formoterol fumarate dihydrate, budesonide and tiotropium bromide hydrate in the pharmaceutical composition are 0.001%-0.4%, 0.02%-4% and 0.005%-0.8%, respectively. The pharmaceutical composition provided by the invention is in a dry powder form and is used for inhalation treatment of patients, and the dry powder inhalant has obviously better characteristics compared with sprays and aerosols, and is convenient to carry and easy to operate; medicines in the dry powder form have better stability at room temperature and less susceptibility to microbial contamination; and the most significant progress of the pharmaceutical composition lies in synchronous entering of the medicine powder into a respiratory tract with spontaneous breathing of a patient, so the purpose of specific medicine delivery to the lung is achieved, and difficult coordination and cooperation in the medicine delivery do not exist.
Description
Technical field
The present invention relates to the pharmaceutical composition for treatment of respiratory diseases, further relate to the pharmaceutical composition and preparation method thereof that one treats bronchial asthma, chronic obstructive pulmonary disease (COPD).
Background technology
Asthma is a kind of common chronic respiratory system diseases, and according to WHO (World Health Organization (WHO)) statistics, the patient of global asthma is up to 2.75 hundred million people.Developed country about has 10% population to perplex by this, and the sickness rate of the current asthma of China is 1%, and child morbidity is about 3-5%, is comparatively significantly increased before 10 years.Along with the air pollution in global range and ecological deterioration, the M & M of asthma is in rising trend, has become a kind of main chronic disease threatening public health, has had every year and die from asthma more than 180,000 people.The common drug preventing and treating asthma at present is mainly divided into two large classes: one is anti-inflammatory drug, and two is bronchodilators.And anti-inflammatory drug mainly comprises: glucocorticoids, anti-leukotriene medicine and inflammatory mediator blocker etc.Bronchodilator mainly contains beta-2-adrenoreceptor agonists, M cholinoceptor blocker, theophylline class medicine etc.
Chronic obstructive pulmonary disease (Chronic obstructive Pulmonary Disease, COPD) refer to that a kind of not exclusively reversible flow limitation is the disease of feature, flow limitation is Progressive symmetric erythrokeratodermia development, how reacts relevant to the abnormal inflammatory of pulmonary to deleterious particle and gas.COPD is a kind of chronic, long-term lysis, it is characterized by that irreversible forced expiratory volume in one second (FEVI) reduces, the performance of dyspnea and other respiratory symptoms increases the weight of, progressive health status is damaged.Specifically comprise chronic bronchitis and emphysema two kinds of diseases.COPD occupies the 12 of Present Global sickness rate and the 4th of the cause of the death.According to estimates, to the year two thousand twenty, COPD will be only second to coronary heart disease and cerebrovascular disease and becomes the 5th, the whole world and disable and the 3rd lethal disease.If the drug main of the clinical COPD of being used for the treatment of palliates a disease symptom at present, a kind of medicine that can delay decline in pulmonary function or respiratory tract obstruction is not also had to occur.
The drug main of current treatment COPD will comprise the fixed dosage compound preparation etc. of inhaled corticosteroids together (ICS), fugitive and long-acting broxaterol (SABA, LABA), M-receptor antagonist (LAMA), phosphodiesteraseⅳ inhibitor (theophylline, Xi Luosite, roflumilast) and LABA and LAMA composition.Wherein, anticholinergic agent (M-receptor antagonist) can block human body cholinergic (fan walks) the nerve release bronchial muscular spasm that causes of acetylcholine and firewood liquid secretion increasing, be known as a line medication for the treatment of COPD by scholars, evidence show that anticholinergic agent has become the first-selection medicine of COPD patient in recent years.Glucocorticoid is the medicine of the most effective antiallergic action inflammation, obviously can suppress airway inflammation, be mainly used in the disease progression to severe chronic obstructive pulmonary disease in reducing, but life-time service side effect is larger.Beta 2 receptor specific binding in broxaterol and airway smooth muscle also activates this receptor, and can relax airway smooth muscle, reduces airway resistance.
Tiotropium bromide (Tiotropium Bromide) is by the induction type bronchiectasis medicine of one of the exploitation of German Boehringer Ingelheim company novel treatment chronic obstructive pulmonary disease, it is by blocking the effect of acetylcholine with M3 receptors bind thus alleviating the spasm of bronchial smooth muscle, suck and once curative effect can continue more than 24 hours, be first and can produce the effectively lasting medicine strengthening pulmonary function effect with 1 time on the one inhalation.
Formoterol (Formoterol) is the long-acting beta-2-adrenoreceptor agonists of one developed by Japanese Yamanouchi company, is used for the treatment of the non-asthmatic airways disease of chronic bronchial asthma, exercise-induced asthma, Nocturnal, chronic obstructive pulmonary disease and child.Formoterol especially with rapid-action, long action time, few side effects for feature, become the choice drug for the treatment of asthma in acute attack, be particularly useful for treatment night-time attack asthma.
The glucocorticoid of the efficient local anti-inflammatory effect of budesonide (Budesonide).It can strengthen the stability of endotheliocyte, smooth muscle cell and lysosome membrane, Immunosuppression reaction and the synthesis of reduction antibody, thus the release of the activity media such as histamine is reduced and active reduction, and can alleviate antigen-antibody in conjunction with time the enzymatic processes that excites, suppress the synthesis of bronchoconstriction material and release and alleviate the contractile response of smooth muscle.Be used for the treatment of the asthma for Corticodependence or dependent/non-dependent and COPD patient clinically.
The existing treatment of asthma and COPD can not be satisfactory.Although the medicine such as inhaled corticosteroids together, beta-2-adrenoreceptor agonists, M-receptor antagonist, phosphodiesteraseⅳ inhibitor applied clinically is at present for remissive treatment asthma and COPD, but clinical treatment outcome shows, be used alone a class medicine, particularly for moderate to severe asthma and COPD patient, be difficult to obtain good clinical efficacy.In view of the high prevalence of these diseases, be starved of improvement, more effective and Results more easily.
Summary of the invention
The object of the invention is to provide the pharmaceutical composition of a kind of new treatment chronic obstructive pulmonary disease (COPD), bronchial asthma, provides its preparation method simultaneously.
The present invention is for reaching its object, and the technical scheme of employing is as follows:
A kind of pharmaceutical composition for treatment of respiratory diseases, containing active component and pharmaceutically acceptable carrier, wherein said active component comprises formoterol fumarate dihydrate, budesonide and tiotropium bromide monohydrate, and the percentage by weight of three in pharmaceutical composition respectively is 0.001%-0.4%, 0.02%-4%, 0.005%-0.8%.
Preferably, formoterol fumarate dihydrate, budesonide and the percentage by weight of tiotropium bromide monohydrate three in pharmaceutical composition respectively are 0.02%-0.4%, 0.4%-4%, 0.04%-0.8%.
More preferred, the percentage by weight of formoterol fumarate dihydrate in pharmaceutical composition is 0.04%-0.3%; And/or the percentage by weight of budesonide in pharmaceutical composition is 0.6%-3.2%; And/or the percentage by weight of tiotropium bromide monohydrate in pharmaceutical composition is 0.08%-0.6%.
Further, in pharmaceutical composition except active matter, surplus can be carrier.The percentage by weight of described carrier in pharmaceutical composition is preferably 94.8 ~ 99.54%, more preferably 95.9%-99.28%.
Further, described carrier is selected from least one in monosaccharide, disaccharide, polysaccharide, sugar alcohol, such as arabinose, glucose, fructose, ribose, mannose, sucrose, trehalose, lactose, maltose, starch, glucosan or mannitol, wherein preferred with lactose.
Preferably, described pharmaceutical composition is the dry powder form that can suck for patient.Further, for enabling drug powder reach respiratory tract lower end, the mean diameter of active component, up to about 10 μMs, such as 0.1 to 5 μM, is preferably 1 to 5 μM.If any, the maximum particle diameter of solid carrier is generally 300 μMs, and be preferably 212 μMs at the most, mean diameter is suitably 40 to 100 μMs, such as 50 to 75 μMs.In dry powder composite, the particle diameter of active component and the particle diameter of solid carrier can be reduced to desired level by conventional method, such as grinding, microprecipitation, spraying dry, lyophilization or recrystallization from supercritical medium in air jet mill, ball mill or vibromill.
The pharmaceutical composition of dry powder form can be packed in gelatin or plastic capsule, or in bubble eye, is used in dry powder and sucks in medical instrument, or be prepared into Foradil Aerolizer formoterol fumarate with other suitable methods, through special doser administration.Preferably, in the dosage unit of formoterol fumarate dihydrate, budesonide and tiotropium bromide monohydrate and carrier, their content makes the gross weight of every capsules powder be 5mg to 50mg.Or dry powder can be included in multi-dose dry powder as Drug Storage and suck in medical instrument.
Second aspect present invention provides a kind of method preparing pharmaceutical composition as described above, and described pharmaceutical composition is the dry powder form that can suck for patient, and its preparation comprises the steps:
(1) each component is taken by formula;
(2) formoterol fumarate dihydrate, tiotropium bromide monohydrate are mixed with a small amount of carrier, and micronization;
(3) by budesonide micronization;
(4) pulverizing of residue carrier is prepared into fine grained solid support part;
(5) by step (2), (3) and step (4) gained each several part mix homogeneously.
The superiority of this preparation method is: because the content of principal agent formoterol fumarate dihydrate, tiotropium bromide monohydrate is very low, belong to low dosage high-activity drug, therefore, Component Vectors micronization together with formoterol fumarate dihydrate, tiotropium bromide one hydration can reduce the loss of medicine in micronization, and is convenient to mixing.
Pharmaceutical composition provided by the invention, its tiotropium bromide contained, formoterol and budesonide supplement each other in pharmacodynamic properties, can more effective treatment asthma and COPD.In addition, because the dosage of single compound is in the composition lower, this combination is used can to reduce the incidence rate of ill effect.In addition, the compliance of patient also increases.
Foradil Aerolizer formoterol fumarate (Dry Powder Inhalation, DPI) mean micronized medicine or with carrier with capsule, vesicle or multiple dose reservoir type, adopt special powder inhaler, initiatively suck the preparation of atomization medicine to pulmonary by patient, there is the features such as targeting, efficient, quick-acting, toxic and side effects is little.The invention provides the dry powder form of pharmaceutical composition, for patient's Inhalation in Treating, the feature of Foradil Aerolizer formoterol fumarate is obviously better than spray and aerosol, and it is easy to carry, is easy to operation.The medicine of dry powder form at room temperature has better stability, be not subject to the pollution of microorganism, and its progress the most significantly leans on the autonomous respiration of patient to make drug powder synchronously enter respiratory tract, can reach the object of pulmonary's site-specific delivery of drugs, there is not administration coordinated difficulty.Other advantages of Foradil Aerolizer formoterol fumarate comprise can effectively for low dosage and high dose medicament suction or spray into administration, without the need to any propellant, avoid the pollution to atmospheric environment and respiratory tract.Medicine is with capsule or vesicle form administration, and dosage is accurate, dangerous without overdose administration; Not containing the solvent such as antiseptic and ethanol, to pathological changes mucosa nonirritant, larger dose administration can be realized.
Accompanying drawing explanation
Fig. 1: different pharmaceutical group mouse lung tissue pathological change (HE, X200)
Detailed description of the invention
Below in conjunction with drawings and Examples, technical scheme of the present invention is described further:
Embodiment 1:
A pharmaceutical composition for dry powder form, its prescription is as shown in the table:
| Supplementary material | Consumption (mg) |
| Formoterol fumarate dihydrate (A) | 40 |
| Budesonide (B) | 800 |
| Tiotropium bromide monohydrate (C) | 100 |
| Lactose monohydrate | 99060 |
| Make | 10000 |
Preparation method:
1) by below comminution by gas stream to 10 after the carrier lactose equal increments mix homogeneously of (A), (C) and 9 times amount μm, particle fraction is made.
2) by (B) below comminution by gas stream to 10 μm, make particle fraction.
3) appropriate carrier lactose is milled to particle diameter less than 212 μm, is prepared into fine grained solid support.
4) by 1), 2) gained micropowder is disposable adds 3) in the particulate of gained, detection level after mixing, according to content fill capsule.
Embodiment 2-129
Grin 1 substantially identical with enforcement, but component contained by each corresponding embodiment uses the amount of composition shown in following table:
Embodiment 130 compositions is studied the therapeutic effect of mouse asthma
1, laboratory animal and grouping:
SPF level BALB/c mouse, female, 6-7 week age, body weight 18-20 gram.Ad lib removes special feedstuff and the water of ovalbumin (not containing egg).Be divided into following group at random:
Normal group (n=8): normal saline sensitization, excite and intervene; This group of hereinafter referred is normal group;
Asthma matched group (n=8): OVA sensitization, to excite, normal saline intervention; This group of hereinafter referred is asthma group;
Budesonide group (n=8): OVA sensitization, to excite, budesonide normal saline solution (200ug/ml) is intervened;
Formoterol group (n=8): OVA sensitization, to excite, formoterol fumarate dihydrate normal saline solution (10ug/ml) is intervened;
Tiotropium bromide group (n=8): OVA sensitization, to excite, tiotropium bromide monohydrate normal saline solution (50ug/ml) is intervened; Budesonide+formoterol group (n=8): OVA sensitization, to excite, two kinds of medication combined interventions, budesonide (200ug/ml) in mixed liquor, formoterol fumarate dihydrate (10ug/ml); Hereafter this group is referred to as cloth+good fortune group;
Budesonide+tiotropium bromide group (n=8): OVA sensitization, to excite, two kinds of medication combined interventions, budesonide (200ug/ml) in mixed liquor, tiotropium bromide monohydrate (50ug/ml); This group of hereinafter referred is cloth+thiophene group;
Formoterol+tiotropium bromide group (n=8): OVA sensitization, to excite, two kinds of medication combined interventions, formoterol fumarate dihydrate (10ug/ml) in mixed liquor, tiotropium bromide monohydrate (50ug/ml); This group of hereinafter referred is good fortune+thiophene group;
Budesonide+formoterol+tiotropium bromide group (n=8): OVA sensitization, to excite, three kinds of medication combined interventions, budesonide (200ug/ml) in mixed liquor, formoterol fumarate dihydrate (10ug/ml), tiotropium bromide monohydrate (50ug/ml); This group of hereinafter referred is cloth+good fortune+thiophene group.
2, asthmatic model preparation and pharmaceutical intervention:
In experiment flow the 0th, within 7,14 days, give lumbar injection 10 μ g OVA+1mg Al (OH)
3normal saline suspension 200 μ L sensitization.Within 28-30 or 28-33 days, give till atomization 1%OVA normal saline excites 30min or occur the outbreak of asthma sample in experiment flow.Each group of mice all excites front 1h to give relative medicine or normal saline intervention in the mode of atomization in OVA, and often organizing medicinal atomized respiratory time is 30min, and atomized soln amount is about 5ml.Start acetylcholine after last atomized medicine introducing 12h to excite.The airway reactivity of mice is detected by noinvasive pulmonary function test method in body.Analyze bronchoalveolar lavage fluid (BALF) TCS and differential counting, observe lung tissue disease of science.
3, different pharmaceutical and drug regimen are on the impact of mouse asthma airway reactivity (Penh/NS)
Normal group airway reactivity (Penh/NS), significantly declines when 50-200mg/ml all lower than asthma matched group when the Mch concentration of 6.25-200mg/ml.Budesonide, tiotropium bromide individually dosed when the Mch concentration of 50-200mg/ml airway reactivity significantly lower than asthma matched group, tiotropium bromide group declines more remarkable, formoterol group airway hyperreactivity when the Mch concentration of 6.25-200mg/ml has downward trend, but no difference of science of statistics.Three kinds of any two kinds of associatings of medicine or three kinds of administering drug combinations airway reactivity when the Mch concentration of 50-200mg/ml significantly reduce, and effect is better than individually dosed.
Table 1 different pharmaceutical is on the impact of mouse asthma airway resistance (Penh/NS)
Note: vs asthma contrast * p<0.05, * * p<0.01, * * * p<0.001
4, different pharmaceutical and drug regimen are on the impact of mouse asthma airway reactivity PC100
Compare with Normal group, asthma matched group PC100 downward trend; Tiotropium bromide and each administering drug combinations group compare with asthma matched group, and PC100 all significantly raises, and the results are shown in Table shown in 2.
Table 2 different pharmaceutical is on the impact of airway resistance PC100
Note: vs asthma contrast * p<0.05, * * p<0.01, * * * p<0.001
5, different pharmaceutical and drug regimen are on the impact of mouse asthma BALF cell counting and Eos ratio
See table 3, compare with normal group, asthma group BALF TCS significantly rises (p<0.001).Compare with asthma group, time individually dosed, the remarkable BALF TCS of budesonide declines (p<0.01), and formoterol, tiotropium bromide have downward trend.During administering drug combinations, budesonide+tiotropium bromide, budesonide+formoterol significantly decline (p<0.01), tiotropium bromide+formoterol has downward trend, and three administrations have the decline (p<0.001) of highly significant.Three administering drug combinations groups are more individually dosed and the decline of two administering drug combinations BALF total cellular score is more obvious.
Compare with normal group, asthma group BALF cell Eos ratio significantly rises (p<0.01).Compare with asthma group, the remarkable BALF TCS of budesonide declines (p<0.05), and formoterol, tiotropium bromide have downward trend.During administering drug combinations, general budesonide+tiotropium bromide and budesonide+formoterol significantly decline (p<0.05), tiotropium bromide+formoterol has downward trend, and three administrations have decline (p<0.01) more significantly.
Table 3. different pharmaceutical group mice BALF TCS, Eos proportional counter
Note: vs asthma contrast * p<0.05, * * p<0.01, * * * p<0.001, compares #p<0.05 with three administrations, ##p<0.01
6, different pharmaceutical and drug regimen are on the impact of asthmatic mouse pathology
Fig. 1 is shown in the pathological change of different pharmaceutical group mouse lung tissue, and as seen from Figure 1, normal group mouse bronchial, blood vessel and alveolar structure are clear, air flue Ciliated epithelium marshalling; The blood vessel of severe, peribronchitis (inflammatory cell infiltration, based on Eos infiltration) and edema in mouse asthma, tube chamber sepage, part alveolar structure destroys, mild hyperaemia edema under bronchiolar epithelium arrangement disorder, mucosa; Each administration group pathology comparatively asthma group is all improved, and diastole agent treatment group pathology improves less, still visible obviously inflammatory cell infiltration around bronchus, blood vessel; Containing steroid group, mice pathology improves obviously, degree of taking a favourable turn or minute quantity inflammatory cell infiltration around bronchus, blood vessel.
The above, it is only preferred embodiment of the present invention, not any pro forma restriction is done to the present invention, therefore all contents not departing from technical solution of the present invention, according to technical spirit of the present invention to any simple modification made for any of the above embodiments, equivalent variations and modification, all still belong in the scope of technical solution of the present invention.
Claims (10)
1. the pharmaceutical composition for chronic obstructive pulmonary disease, treating asthma, it is characterized in that, containing active component and pharmaceutically acceptable carrier, wherein said active component comprises formoterol fumarate dihydrate, budesonide and tiotropium bromide monohydrate, and the percentage by weight of three in pharmaceutical composition respectively is 0.001%-0.4%, 0.02%-4%, 0.005%-0.8%.
2. pharmaceutical composition according to claim 1, it is characterized in that, formoterol fumarate dihydrate, budesonide and the percentage by weight of tiotropium bromide monohydrate three in pharmaceutical composition respectively are 0.02%-0.4%, 0.4%-4%, 0.04%-0.8%.
3. pharmaceutical composition according to claim 2, is characterized in that, the percentage by weight of formoterol fumarate dihydrate in pharmaceutical composition is 0.04%-0.3%; And/or the percentage by weight of budesonide in pharmaceutical composition is 0.6%-3.2%; And/or the percentage by weight of tiotropium bromide monohydrate in pharmaceutical composition is 0.08%-0.6%.
4. pharmaceutical composition according to claim 1, is characterized in that, the percentage by weight of described carrier in pharmaceutical composition is 94.8 ~ 99.54%.
5. pharmaceutical composition according to claim 1, is characterized in that, described carrier is selected from least one in monosaccharide, disaccharide, polysaccharide, sugar alcohol.
6. pharmaceutical composition according to claim 5, is characterized in that, described carrier is selected from arabinose, glucose, fructose, ribose, mannose, sucrose, trehalose, lactose, maltose, starch, glucosan or mannitol.
7. pharmaceutical composition according to claim 1, is characterized in that, described pharmaceutical composition is the dry powder form that can suck for patient.
8. pharmaceutical composition according to claim 7, it is characterized in that, the carrier of its carrier contained of described pharmaceutical composition to be mean diameter be fine pulverizing of 40 ~ 100 μm, the mean diameter of its active component contained of described pharmaceutical composition is no more than 10 μm.
9. pharmaceutical composition according to claim 7, is characterized in that, described pharmaceutical composition is present in capsule, bubble eye or dry powder and sucks in medical instrument.
10. prepare a method for the pharmaceutical composition as described in any one of claim 1 ~ 9, it is characterized in that, described pharmaceutical composition is the dry powder form that can suck for patient, and its preparation comprises the steps:
(1) each component is taken by formula;
(2) formoterol fumarate dihydrate, tiotropium bromide monohydrate are mixed with a small amount of carrier, and micronization;
(3) by budesonide micronization;
(4) pulverizing of residue carrier is prepared into fine grained solid support part;
(5) by step (2), (3) and step (4) gained each several part mix homogeneously.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410790703.9A CN104758294A (en) | 2014-12-17 | 2014-12-17 | Inhalation pharmaceutical composition used for treatment of chronic obstructive pulmonary disease (COPD) and asthma and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410790703.9A CN104758294A (en) | 2014-12-17 | 2014-12-17 | Inhalation pharmaceutical composition used for treatment of chronic obstructive pulmonary disease (COPD) and asthma and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104758294A true CN104758294A (en) | 2015-07-08 |
Family
ID=53640626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410790703.9A Pending CN104758294A (en) | 2014-12-17 | 2014-12-17 | Inhalation pharmaceutical composition used for treatment of chronic obstructive pulmonary disease (COPD) and asthma and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104758294A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107998147A (en) * | 2017-11-06 | 2018-05-08 | 广州医科大学附属第医院 | A kind of Neulized inhalation preparation for suppressing or treating COPD and its application |
| CN115315431A (en) * | 2020-03-27 | 2022-11-08 | 基因股份公司 | Budesonide 21-phosphate ester salt and pharmaceutical composition containing same |
| CN116077471A (en) * | 2021-11-08 | 2023-05-09 | 上海臣邦医药科技股份有限公司 | Powder aerosol composition for inhalation and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103347501A (en) * | 2011-02-04 | 2013-10-09 | 诺华股份有限公司 | Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases |
| CN106470700A (en) * | 2014-05-12 | 2017-03-01 | 梯瓦制药欧洲有限责任公司 | For treating the combination of tiotropium bromide, formoterol and the budesonide of COPD |
-
2014
- 2014-12-17 CN CN201410790703.9A patent/CN104758294A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103347501A (en) * | 2011-02-04 | 2013-10-09 | 诺华股份有限公司 | Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases |
| CN106470700A (en) * | 2014-05-12 | 2017-03-01 | 梯瓦制药欧洲有限责任公司 | For treating the combination of tiotropium bromide, formoterol and the budesonide of COPD |
Non-Patent Citations (4)
| Title |
|---|
| 卢丽等: "噻托溴铵联合小剂量布地奈德福莫特罗治疗中重度支气管哮喘并慢性阻塞性肺疾病26例", 《中国药业》 * |
| 张卫东等: "噻托溴铵及噻托溴铵联合布地奈德福莫特罗治疗COPD疗效分析", 《现代生物医学进展》 * |
| 李翠芬等: "联合吸入布地奈德/福莫特罗和噻托溴铵治疗老年慢性阻塞性肺疾病临床研究", 《泰山医学院学报》 * |
| 迟春花: "药物对慢性阻塞性肺疾病临床进程的干预作用", 《世界临床药物》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107998147A (en) * | 2017-11-06 | 2018-05-08 | 广州医科大学附属第医院 | A kind of Neulized inhalation preparation for suppressing or treating COPD and its application |
| CN115315431A (en) * | 2020-03-27 | 2022-11-08 | 基因股份公司 | Budesonide 21-phosphate ester salt and pharmaceutical composition containing same |
| CN116077471A (en) * | 2021-11-08 | 2023-05-09 | 上海臣邦医药科技股份有限公司 | Powder aerosol composition for inhalation and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100234864B1 (en) | Use of mometasone furoate for treating upper airway passage diseases | |
| CN101756942A (en) | Oral lung inhalation aerosol powder | |
| JP2015519394A (en) | Dry powder for inhalation preparation containing salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for producing the same | |
| JP2019520361A (en) | Compositions, devices and methods for the treatment of alcohol use disorders | |
| UA119773C2 (en) | Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd | |
| KR101475262B1 (en) | Compound composition for inhalation used for treating asthma | |
| CN104758294A (en) | Inhalation pharmaceutical composition used for treatment of chronic obstructive pulmonary disease (COPD) and asthma and preparation method thereof | |
| CN101264092A (en) | Compound preparations with ciclesonide and formoterol as active component and preparation and application thereof | |
| CN107205936B (en) | Composition comprising at least one dry powder obtained by spray drying for increasing the stability of the formulation | |
| CN102448309A (en) | Use of R-Bambuterol as inhaled medicament and combination therapies for treatment of respiratory disorders | |
| WO2007140681A1 (en) | The use of cucurbitacins or cucurbitacin compositions in preparation of medicaments for raising leukocytes | |
| CN101569684B (en) | Inhalation aerosol of plant extract for treating asthma and preparation method | |
| CN111991374A (en) | Rudesivir inhalation aerosol and preparation method thereof | |
| CN103989695A (en) | Pharmaceutical composition for treating bronchial asthma and application thereof | |
| CN111481550A (en) | Pharmaceutical formulation containing tiotropium bromide and arformoterol | |
| CN101249093A (en) | Combination for curing chronic obstructive disease of lung | |
| CN101023953B (en) | Composition for treating bronchia asthma | |
| CN101474191B (en) | Pharmaceutical composition for treating asthma and chronic obstructive pulmonary disease | |
| CN102258504A (en) | Compound salbutamol sulfate and ambroxol hydrochloride inhalation solution | |
| CN104208045A (en) | Compound inhalation preparation containing penicillin antibiotic and glucocorticoid | |
| CN102000089A (en) | Compound preparation with ciclesonide and Arformoterol as active constituents | |
| CN103830208A (en) | H1-receptor-antagonist-containing inhalation preparation | |
| EP1414468B1 (en) | Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders | |
| US20140011784A1 (en) | Method and composition for treating asthma | |
| JP2017503814A (en) | Treatment of partially controlled severe asthma or poorly controlled severe asthma with PDE4 inhibitors (and used in combination with leukotriene modulators) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150708 |
|
| RJ01 | Rejection of invention patent application after publication |